Brainstorm Cell Therapeutics (Nasdaq:BCLI) - Hisse Senedi Fiyatı, Haberler ve Analizler

Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

BCLI Stoklara Genel Bakış

BCLI temel anali̇z
Kar Tanesi Skoru
Değerleme	2/6
Gelecekteki Büyüme	0/6
Geçmiş Performans	0/6
Finansal Sağlık	1/6
Temettüler	0/6

Ödüller

Adil değer tahminimizden 99.7% daha düşük bir oranda işlem görüyor

Kazançlar son 5 yılda yılda 7.5% oranında arttı

Risk Analizi

Negatif hissedar öz sermayesi

Geliri 1 milyon ABD dolarından az ( $0 )

1 yıldan az nakit akışı var

Hissedarlar geçen yıl önemli ölçüde sulandırıldı

+ 4 daha fazla risk

Brainstorm Cell Therapeutics Inc. Rakipler

Vascular Biogenics

NasdaqCM:VBLT

US$12.1m

Vincerx Pharma

NasdaqCM:VINC

US$11.7m

Eagle Pharmaceuticals

OTCPK:EGRX

US$11.7m

BioRestorative Therapies

NasdaqCM:BRTX

US$11.5m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Brainstorm Cell Therapeutics
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$2.25
52 Haftanın En Yüksek Seviyesi	US$11.89
52 Haftanın En Düşük Seviyesi	US$1.96
Beta	0.32
11 Aylık Değişim	-38.22%
3 Aylık Değişim	-58.22%
1 Yıllık Değişim	-15.73%
33 Yıllık Değişim	-95.13%
5 Yıllık Değişim	-95.88%
Halka arzdan bu yana değişim	-55.56%

Son Haberler & Güncellemeler

Recent updates

Brainstorm Cell Therapeutics: Upcoming BLA In ALS

Aug 21

BrainStorm Cell Therapeutics Q2 2022 Earnings Preview

Aug 12

Is Brainstorm Cell Therapeutics (NASDAQ:BCLI) In A Good Position To Invest In Growth?

Aug 05

Is Brainstorm Cell Therapeutics (NASDAQ:BCLI) In A Good Position To Invest In Growth?

Mar 22

Is Brainstorm Cell Therapeutics (NASDAQ:BCLI) In A Good Position To Invest In Growth?

Nov 26

Brainstorm Cell Therapeutics: MSC-NTF Cell Therapy Shows Mid-Stage Promise In PMS

May 30

Is Brainstorm Cell Therapeutics (NASDAQ:BCLI) In A Good Position To Deliver On Growth Plans?

May 02

Here's Why We're Watching Brainstorm Cell Therapeutics' (NASDAQ:BCLI) Cash Burn Situation

Jan 17

BrainStorm completes dosing in Phase 2 MS Study

Dec 18

BrainStorm launches NurOwn Expanded Access Program

Dec 14

What Percentage Of Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Shares Do Insiders Own?

Dec 13

BrainStorm's NurOwn flunks in late-stage ALS study

Nov 17

Hissedar Getirileri

	BCLI	US Biotechs	US Pazar
7D	12.5%	0.6%	0.8%
1Y	-15.7%	27.4%	38.3%

Getiri vs. Endüstri: BCLI geçen yıl % 22.1 oranında getiri sağlayan US Biotechs sektörünün gerisinde kaldı.

Getiri vs Piyasa: BCLI geçen yıl % 34.1 oranında getiri sağlayan US Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is BCLI's price volatile compared to industry and market?
BCLI volatility
BCLI Average Weekly Movement	13.6%
Biotechs Industry Average Movement	9.7%
Market Average Movement	6.2%
10% most volatile stocks in US Market	14.8%
10% least volatile stocks in US Market	3.0%

İstikrarlı Hisse Senedi Fiyatı: BCLI hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.

Zaman İçindeki Volatilite: BCLI 'nin haftalık oynaklığı son bir yılda 20% dan 12% a düştü, ancak hâlâ US hisselerinin %75'inden yüksek.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2000	29	Chaim Lebovits	www.brainstorm-cell.com

Bir biyoteknoloji şirketi olan Brainstorm Cell Therapeutics Inc. nörodejeneratif hastalıkların tedavisi için otolog hücresel tedavilerin geliştirilmesi ve ticarileştirilmesi ile ilgilenmektedir. Şirket, NurOwn tescilli hücre terapisi platformu aracılığıyla, yüksek düzeyde nörotrofik faktörler salgılamak, nöroinflamatuar ve nörodejeneratif hastalık süreçlerini modüle etmek, nöronal sağkalımı teşvik etmek ve nörolojik işlevi geliştirmek için otolog kemik iliği kaynaklı mezenkimal kök hücreleri indüklemek için hücre kültürü yöntemlerinden yararlanmaktadır. Amiyotrofik lateral skleroz tedavisi için Faz III klinik çalışmasını tamamlayan NurOwn'u; ilerleyici multipl skleroz tedavisi için Faz II klinik çalışmasını; ve alzheimer hastalığının yanı sıra diğer nörodejeneratif hastalıkların tedavisi için geliştirmektedir.

Brainstorm Cell Therapeutics Inc. Temel Bilgiler Özeti

Brainstorm Cell Therapeutics'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
BCLI temel i̇stati̇sti̇kler
Piyasa değeri	US$11.96m
Kazançlar(TTM)	-US$12.75m
Gelir(TTM)	n/a

0.0x

P/S Oranı

-0.9x

F/K Oranı

BCLI aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
BCLI gelir tablosu (TTM)
Gelir	US$0
Gelir Maliyeti	US$0
Brüt Kâr	US$0
Diğer Giderler	US$12.75m
Kazançlar	-US$12.75m

Son Raporlanan Kazançlar

Jun 30, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-2.40
Brüt Marj	0.00%
Net Kâr Marjı	0.00%
Borç/Özkaynak Oranı	0%

BCLI uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

BCLI Stoklara Genel Bakış

Ödüller

Risk Analizi

Brainstorm Cell Therapeutics Inc. Rakipler

NasdaqCM:VBLT

US$12.1m

NasdaqCM:VINC

US$11.7m

OTCPK:EGRX

US$11.7m

NasdaqCM:BRTX

US$11.5m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Brainstorm Cell Therapeutics Implements 1-for-15 Reverse Stock Split to Meet Nasdaq's Minimum Bid Price Requirement

New major risk - Financial position

Brainstorm Cell Therapeutics Inc., Annual General Meeting, Sep 16, 2024

Brainstorm Cell Therapeutics Receives Deficiency Notice from Nasdaq Due to Non-Compliance with the Minimum of $35 Million Market Value of Listed Securities Pursuant to Nasdaq Listing Rule 5550(b)(2)

Brainstorm Cell Therapeutics Inc. has filed a Follow-on Equity Offering in the amount of $4 million.

Brainstorm Cell Therapeutics Inc. Reaches Alignment with Fda on Cmc Aspects of Phase 3B Nurown®? Clinical Trial

Recent updates

Brainstorm Cell Therapeutics Implements 1-for-15 Reverse Stock Split to Meet Nasdaq's Minimum Bid Price Requirement

New major risk - Financial position

Brainstorm Cell Therapeutics Inc., Annual General Meeting, Sep 16, 2024

Brainstorm Cell Therapeutics Receives Deficiency Notice from Nasdaq Due to Non-Compliance with the Minimum of $35 Million Market Value of Listed Securities Pursuant to Nasdaq Listing Rule 5550(b)(2)

Brainstorm Cell Therapeutics Inc. has filed a Follow-on Equity Offering in the amount of $4 million.

Brainstorm Cell Therapeutics Inc. Reaches Alignment with Fda on Cmc Aspects of Phase 3B Nurown®? Clinical Trial

New major risk - Revenue and earnings growth

Brainstorm Cell Therapeutics Announces Appointment of Haro Hartounian as EVP and COO

Brainstorm Cell Therapeutics Inc. Announces Non-Compliance Update

Brainstorm Cell Therapeutics Receives Staff Determination Letter from Nasdaq Regarding it Not Regains Compliance with the Minimum Bid Price Requirement by April 29, 2024 and Submits a Hearing Request to the Nasdaq Hearings Panel to Appeal the Staff’s Determination

Brainstorm Cell Therapeutics Inc. Announces Management Changes

BrainStorm Cell Therapeutics Regains Compliance with NASDAQ Minimum Market Value Rule

BrainStorm Cell Therapeutics Inc. Announces Agreement with FDA on Special Protocol Assessment for Phase 3b Trial in ALS

New major risk - Shareholder dilution

BrainStorm Cell Therapeutics Submits Special Protocol Assessment (SPA) Request to FDA for Phase 3b Trial of NurOwn in ALS

Brainstorm Cell Therapeutics Inc. Announces Executive Changes

BrainStorm Cell Therapeutics Announces Outcome of FDA Meeting on NurOwn® in ALS

Brainstorm Cell Therapeutics Receives Notice from Nasdaq Regarding Non-Compliance Market Value of Listed Securities Requirement for Continued Listing on The Nasdaq Capital Market

Brainstorm Cell Therapeutics Inc., Annual General Meeting, Dec 18, 2023

Brainstorm Cell Therapeutics Receives Non-Compliance Notice from Nasdaq Regarding Non-Compliance with the $1.00 Minimum Bid Price Requirement Set Forth in Nasdaq Listing Rule 5550(a)(2)

Brainstorm Cell Therapeutics Receives Non-Compliance Notice from Nasdaq Regarding Non-Compliance with the $1.00 Minimum Bid Price Requirement Set Forth in Nasdaq Listing Rule 5550(a)(2)

Brainstorm Cell Therapeutics Receives Non-Compliance Notice from Nasdaq

Gainey Mckenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Brainstorm Cell Therapeutics Inc

New minor risk - Profitability

BrainStorm Cell Therapeutics Announces Strategic Realignment Prioritizing NurOwn for the Treatment of ALS

Brainstorm Cell Therapeutics Inc. to Report Q2, 2023 Results on Aug 14, 2023

BrainStorm Cell Therapeutics Inc. Appoints Bob Dagher as Executive Vice President and Chief Development Officer

Brainstorm Cell Therapeutics Appoints Nir Naor as Board Member and Audit Committee Chair

New minor risk - Market cap size

Forecast to breakeven in 2025

Brainstorm Cell Therapeutics Inc Announces Resignation of David Setboun as Executive Vice President and Chief Operating Officer

Forecast to breakeven in 2025

BrainStorm Cell Therapeutics Announces Promotion of Dr. Stacy Lindborg to Co-Chief Executive Officer

Brainstorm Cell Therapeutics Inc. Announces Type A Meeting with FDA Granted for NurOwn®

Brainstorm Cell Therapeutics Inc., Annual General Meeting, Jan 10, 2023

BrainStorm Cell Therapeutics Submits Type A Meeting Request to U.S. Food and Drug Administration

Brainstorm Cell Therapeutics Seeks FDA Approval of Mesenchymal Stem Cell Therapy Called NurOwn for the Treatment of ALS

Price target decreased to US$13.00

Brainstorm Cell Therapeutics Inc. Receives Refusal to File Letter from FA for Its New Biologics License Application for Nurown for the Treatment of Als

BrainStorm Presents New Biomarker Analyses from NurOwn's Phase 3 ALS Trial at the ALS ONE Research Symposium

Brainstorm Cell Therapeutics Inc. Announces Peer Reviewed Publication of Results from the Nurown Phase 2 Progressive MS Trial in Multiple Sclerosis Journal

Brainstorm Cell Therapeutics: Upcoming BLA In ALS

Brainstorm Cell Therapeutics Inc. Submits Biologics License Application to the U.S. Food and Drug Administration for NurOwn for the Treatment of Amyotrophic Lateral Sclerosis

BrainStorm Cell Therapeutics Q2 2022 Earnings Preview

Is Brainstorm Cell Therapeutics (NASDAQ:BCLI) In A Good Position To Invest In Growth?

Brainstorm Cell Therapeutics Inc. Appoints Antal Pearl-Lendner as Chief Legal Counsel

BrainStorm Cell Therapeutics Inc. Announces Presentation of Nurown® Exosome Preclinical Data At ISCT 2022 San Francisco Meeting

Price target increased to US$11.00

Is Brainstorm Cell Therapeutics (NASDAQ:BCLI) In A Good Position To Invest In Growth?

U.S. Food and Drug Administration Authorizes Further Brainstorm Cell Therapeutics Inc.'s Nurown Dosing Under Expanded Access Program

Brainstorm Cell Therapeutics Announces Peer Reviewed Publication of Nurown's® Phase 3 Study for Als in Muscle and Nerve

BrainStorm Cell Therapeutics Announces the Presentation of New Analyses from the Phase 3 Trial of NurOwn® in ALS at the 4th Annual ALS ONE Research Symposium

Is Brainstorm Cell Therapeutics (NASDAQ:BCLI) In A Good Position To Invest In Growth?

No longer forecast to breakeven

Brainstorm Cell Therapeutics Inc.(NasdaqCM:BCLI) dropped from Russell 3000 Growth Index

Brainstorm Cell Therapeutics: MSC-NTF Cell Therapy Shows Mid-Stage Promise In PMS

Is Brainstorm Cell Therapeutics (NASDAQ:BCLI) In A Good Position To Deliver On Growth Plans?

BrainStorm Cell Therapeutics EPS beats by $0.07

New 90-day low: US$4.21